APPROPRIATE APIXABAN PROPHYLAXIS IN ONCOLOGY PATIENTS TO EVALUATE REDUCTION IN ADVERSE THROMBOEMBOLIC EVENTS

Bristol-Myers Squibb Company

Application Filed: 2007-01-18

Trademark Application Details

Status

606

Dead/Abandoned

ABANDONED - NO STATEMENT OF USE FILED

Research	OneLook Acronym Finder
Serial Number	77085405
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Attorney Name	Tanya Fickenscher Leonard
Law Office Assigned	L50
Employee Name	HUSSAIN, TASNEEM

Timeline

2007-01-18	Application Filed
2008-01-22	Published for Opposition
2010-09-27	Location: INTENT TO USE SECTION
2011-05-16	Abandon
2011-05-16	Status: Dead/Abandoned
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	Bristol-Myers Squibb Company
Address	345 Park Avenue New York DE 10154
Legal Entity Type	Corporation
Legal Entity State	DE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

Tanya Fickenscher Leonard
Bristol-Myers Squibb Company
345 Park Avenue
New York NY 10154

Good, Services, and Codes

International Codes:	42
U.S. Codes:	100,101

Type Code	Type
D10000	"APIXABAN PROPHYLAXIS IN ONCOLOGY PATIENTS TO EVALUATE REDUCTION IN ADVERSE THROMBOEMBOLIC EVENTS"

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED IN TRAM	2007-01-23	1 NWAP I:Incoming Correspondence
ASSIGNED TO EXAMINER	2007-05-07	2 DOCK D:Assigned to Examiner
NON-FINAL ACTION WRITTEN	2007-05-17	3 CNRT R:Renewal
NON-FINAL ACTION MAILED	2007-05-18	4 CNRT F:First Action
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2007-11-02	5 TROA I:Incoming Correspondence
CORRESPONDENCE RECEIVED IN LAW OFFICE	2007-11-02	6 CRFA I:Incoming Correspondence
TEAS/EMAIL CORRESPONDENCE ENTERED	2007-11-02	7 TEME I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER	2007-11-13	8 CNSA P:
ASSIGNED TO LIE	2007-12-20	9 ALIE A:Allowance for Publication
LAW OFFICE PUBLICATION REVIEW COMPLETED	2007-12-20	10 PREV O:Outgoing Correspondence
NOTICE OF PUBLICATION	2008-01-02	11 NPUB O:Outgoing Correspondence
PUBLISHED FOR OPPOSITION	2008-01-22	12 PUBO A:Allowance for Publication
NOA MAILED - SOU REQUIRED FROM APPLICANT	2008-04-15	13 NOAM O:Outgoing Correspondence
TEAS EXTENSION RECEIVED	2008-09-29	14 EEXT I:Incoming Correspondence
EXTENSION 1 FILED	2008-09-29	15 EXT1 S:
EXTENSION 1 GRANTED	2008-09-29	16 EX1G S:
TEAS EXTENSION RECEIVED	2009-04-02	17 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL	2009-04-14	18 AITU A:Allowance for Publication
EXTENSION 2 FILED	2009-04-02	19 EXT2 S:
EXTENSION 2 GRANTED	2009-04-14	20 EX2G S:
ASSIGNED TO EXAMINER	2009-05-29	21 DOCK D:Assigned to Examiner
TEAS EXTENSION RECEIVED	2009-09-17	22 EEXT I:Incoming Correspondence
EXTENSION 3 FILED	2009-09-17	23 EXT3 S:
EXTENSION 3 GRANTED	2009-09-21	24 EX3G S:
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED	2009-12-17	25 REAP I:Incoming Correspondence
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED	2009-12-17	26 ARAA I:Incoming Correspondence
TEAS EXTENSION RECEIVED	2010-03-19	27 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL	2010-04-13	28 AITU A:Allowance for Publication
EXTENSION 4 FILED	2010-03-19	29 EXT4 S:
EXTENSION 4 GRANTED	2010-04-13	30 EX4G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED	2010-04-14	31 EXRA O:Outgoing Correspondence
TEAS EXTENSION RECEIVED	2010-09-21	32 EEXT I:Incoming Correspondence
EXTENSION 5 FILED	2010-09-21	33 EXT5 S:
EXTENSION 5 GRANTED	2010-09-27	34 EX5G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED	2010-09-28	35 EXRA O:Outgoing Correspondence
ABANDONMENT - NO USE STATEMENT FILED	2011-05-16	36 ABN6 S:
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED	2011-05-16	37 MAB6 O:Outgoing Correspondence

Similar Marks

Mark Image Registration \| Serial	Company Trademark Application Date
APPROPRIATE APIXABAN PROPHYLAXIS IN ONCOLOGY PATIENTS TO EVALUATE REDUCTION IN ADVERSE THROMBOEMBOLIC EVENTS 85294799 not registered Dead/Abandoned	Bristol-Myers Squibb Company 2011-04-14
APPROPRIATE APIXABAN PROPHYLAXIS IN ONCOLOGY PATIENTS TO EVALUATE REDUCTION IN ADVERSE THROMBOEMBOLIC EVENTS 77085405 not registered Dead/Abandoned	Bristol-Myers Squibb Company 2007-01-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.